[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.200.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Diagnosis and Treatment of Pituitary AdenomasA Review

Educational Objective
To learn about the evaluation and management of pituitary adenomas.
1 Credit CME
Abstract

Importance  Pituitary adenomas may hypersecrete hormones or cause mass effects. Therefore, early diagnosis and treatment are important.

Observations  Prevalence of pituitary adenomas ranges from 1 in 865 adults to 1 in 2688 adults. Approximately 50% are microadenomas (<10 mm); the remainder are macroadenomas (≥10 mm). Mass effects cause headache, hypopituitarism, and visual field defects. Treatments include transsphenoidal surgery, medical therapies, and radiotherapy. Prolactinomas account for 32% to 66% of adenomas and present with amenorrhea, loss of libido, galactorrhea, and infertility in women and loss of libido, erectile dysfunction, and infertility in men; they are generally treated with the dopamine agonists cabergoline and bromocriptine. Growth hormone–secreting tumors account for 8% to 16% of tumors and usually present with enlargement of the lips, tongue, nose, hands, and feet and are diagnosed by elevated insulin-like growth factor 1 levels and growth hormone levels; initial treatment is surgical. Medical therapy with somatostatin analogues, cabergoline, and pegvisomant is often also needed. Adrenocorticotropic hormone (ACTH)–secreting tumors account for 2% to 6% of adenomas and are associated with obesity, hypertension, diabetes, and other morbidity. Measurement of a late-night salivary cortisol level is the best screening test but petrosal sinus sampling for ACTH may be necessary to distinguish a pituitary from an ectopic source. The primary treatment of Cushing disease (hypercortisolism due to ACTH-producing adenomas, which is the cause in approximately 65% of the cases of hypercortisolism) is adenoma resection and medical therapies including ketoconazole, mifepristone, and pasireotide. Hyperthyroidism due to thyroid-stimulating hormone–secreting tumors accounts for 1% of tumors and is treated with surgery and somatostatin analogues if not surgically cured. Clinically nonfunctioning adenomas account for 15% to 54% of adenomas and present with mass effects; surgery is generally required, although incidentally found tumors can be followed if they are asymptomatic.

Conclusions and Relevance  Patients with pituitary adenomas should be identified at an early stage so that effective treatment can be implemented. For prolactinomas, initial therapy is generally dopamine agonists. For all other pituitary adenomas, initial therapy is generally transsphenoidal surgery with medical therapy being reserved for those not cured by surgery.

Sign in to take quiz and track your certificates

Buy This Activity
Article Information

Corresponding Author: Mark E. Molitch, MD, Division of Endocrinology Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N Michigan Ave, Ste 530, Chicago, IL 60611 (molitch@northwestern.edu).

Conflict of Interest Disclosures: Dr Molitch has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. He reports having received research grant support from Novartis, Ipsen, Corcept, and Chiasma and has received honoraria for consultations from Novartis, Ipsen, Corcept, Chiasma, and Pfizer.

References
1.
Molitch  ME.  Nonfunctioning pituitary tumors.  Handb Clin Neurol. 2014;124:167-184.PubMedGoogle Scholar
2.
Hall  WA, Luciano  MG, Doppman  JL, Patronas  NJ, Oldfield  EH.  Pituitary magnetic resonance imaging in normal human volunteers.  Ann Intern Med. 1994;120(10):817-820.PubMedGoogle ScholarCrossref
3.
Famini  P, Maya  MM, Melmed  S.  Pituitary magnetic resonance imaging for sellar and parasellar masses.  J Clin Endocrinol Metab. 2011;96(6):1633-1641.PubMedGoogle ScholarCrossref
4.
Daly  AF, Rixhon  M, Adam  C, Dempegioti  A, Tichomirowa  MA, Beckers  A.  High prevalence of pituitary adenomas.  J Clin Endocrinol Metab. 2006;91(12):4769-4775.PubMedGoogle ScholarCrossref
5.
United States Food and Drug Administration.  FDA drug safety communication. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362444.pdf. Accessed January 4, 2017.
6.
Fontana  E, Gaillard  R.  Epidémiologie des adénomes hypophysaires [in French].  Rev Med Suisse. 2009;5(223):2172-2174.PubMedGoogle Scholar
7.
Fernandez  A, Karavitaki  N, Wass  JA.  Prevalence of pituitary adenomas.  Clin Endocrinol (Oxf). 2010;72(3):377-382.PubMedGoogle ScholarCrossref
8.
Raappana  A, Koivukangas  J, Ebeling  T, Pirilä  T.  Incidence of pituitary adenomas in Northern Finland in 1992-2007.  J Clin Endocrinol Metab. 2010;95(9):4268-4275.PubMedGoogle ScholarCrossref
9.
Gruppetta  M, Mercieca  C, Vassallo  J.  Prevalence and incidence of pituitary adenomas: a population based study in Malta.  Pituitary. 2013;16(4):545-553.PubMedGoogle ScholarCrossref
10.
Tjörnstrand  A, Gunnarsson  K, Evert  M,  et al.  The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011.  Eur J Endocrinol. 2014;171(4):519-526.PubMedGoogle ScholarCrossref
11.
Agustsson  TT, Baldvinsdottir  T, Jonasson  JG,  et al.  The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study.  Eur J Endocrinol. 2015;173(5):655-664.PubMedGoogle ScholarCrossref
12.
Raverot  G, Jouanneau  E, Trouillas  J.  Management of endocrine disease.  Eur J Endocrinol. 2014;170(4):R121-R132.PubMedGoogle ScholarCrossref
13.
Buchfelder  M, Schlaffer  S.  Imaging of pituitary pathology.  Handb Clin Neurol. 2014;124:151-166.PubMedGoogle Scholar
14.
Cooper  O, Melmed  S.  Subclinical hyperfunctioning pituitary adenomas.  Best Pract Res Clin Endocrinol Metab. 2012;26(4):447-460.PubMedGoogle ScholarCrossref
15.
Melmed  S.  Pathogenesis of pituitary tumors.  Nat Rev Endocrinol. 2011;7(5):257-266.PubMedGoogle ScholarCrossref
16.
Swearingen  B.  Update on pituitary surgery.  J Clin Endocrinol Metab. 2012;97(4):1073-1081.PubMedGoogle ScholarCrossref
17.
Ammirati  M, Wei  L, Ciric  I.  Short-term outcome of endoscopic vs microscopic pituitary adenoma surgery: a systematic review and meta-analysis.  J Neurol Neurosurg Psychiatry. 2013;84(8):843-849.PubMedGoogle ScholarCrossref
18.
Ciric  I, Ragin  A, Baumgartner  C, Pierce  D.  Complications of transsphenoidal surgery.  Neurosurgery. 1997;40(2):225-236.PubMedGoogle ScholarCrossref
19.
Barker  FG  II, Klibanski  A, Swearingen  B.  Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000.  J Clin Endocrinol Metab. 2003;88(10):4709-4719.PubMedGoogle ScholarCrossref
20.
Cote  DJ, Alzarea  A, Acosta  MA,  et al.  Predictors and rates of delayed symptomatic hyponatremia after transsphenoidal surgery: a systematic review.  World Neurosurg. 2016;88:1-6.PubMedGoogle ScholarCrossref
21.
Loeffler  JS, Shih  HA.  Radiation therapy in the management of pituitary adenomas.  J Clin Endocrinol Metab. 2011;96(7):1992-2003.PubMedGoogle ScholarCrossref
22.
Ding  D, Starke  RM, Sheehan  JP.  Treatment paradigms for pituitary adenomas.  J Neurooncol. 2014;117(3):445-457.PubMedGoogle ScholarCrossref
23.
Gillam  MP, Molitch  ME, Lombardi  G, Colao  A.  Advances in the treatment of prolactinomas.  Endocr Rev. 2006;27(5):485-534.PubMedGoogle ScholarCrossref
24.
Casanueva  FF, Molitch  ME, Schlechte  JA,  et al.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.  Clin Endocrinol (Oxf). 2006;65(2):265-273.PubMedGoogle ScholarCrossref
25.
Melmed  S, Casanueva  FF, Hoffman  AR,  et al; Endocrine Society.  Diagnosis and treatment of hyperprolactinemia.  J Clin Endocrinol Metab. 2011;96(2):273-288.PubMedGoogle ScholarCrossref
26.
Karavitaki  N, Thanabalasingham  G, Shore  HC,  et al.  Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition?  Clin Endocrinol (Oxf). 2006;65(4):524-529.PubMedGoogle ScholarCrossref
27.
Ono  M, Miki  N, Kawamata  T,  et al.  Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.  J Clin Endocrinol Metab. 2008;93(12):4721-4727.PubMedGoogle ScholarCrossref
28.
Delgrange  E, Daems  T, Verhelst  J, Abs  R, Maiter  D.  Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.  Eur J Endocrinol. 2009;160(5):747-752.PubMedGoogle ScholarCrossref
29.
Simonis  G, Fuhrmann  JT, Strasser  RH.  Meta-analysis of heart valve abnormalities in Parkinson disease patients treated with dopamine agonists.  Mov Disord. 2007;22(13):1936-1942.PubMedGoogle ScholarCrossref
30.
Valassi  E, Klibanski  A, Biller  BM.  Clinical Review#.  J Clin Endocrinol Metab. 2010;95(3):1025-1033.PubMedGoogle ScholarCrossref
31.
Molitch  ME.  Management of medically refractory prolactinoma.  J Neurooncol. 2014;117(3):421-428.PubMedGoogle ScholarCrossref
32.
Noronha  S, Stokes  V, Karavitaki  N, Grossman  A.  Treating prolactinomas with dopamine agonists.  Endocrine. 2016;51(2):205-210.PubMedGoogle ScholarCrossref
33.
Molitch  ME.  Endocrinology in pregnancy.  Eur J Endocrinol. 2015;172(5):R205-R213.PubMedGoogle ScholarCrossref
34.
Melmed  S.  Medical progress: acromegaly.  N Engl J Med. 2006;355(24):2558-2573.PubMedGoogle ScholarCrossref
35.
Borson-Chazot  F, Garby  L, Raverot  G, Claustrat  F, Raverot  V, Sassolas  G; GTE group.  Acromegaly induced by ectopic secretion of GHRH.  Ann Endocrinol (Paris). 2012;73(6):497-502.PubMedGoogle ScholarCrossref
36.
Colao  A, Ferone  D, Marzullo  P, Lombardi  G.  Systemic complications of acromegaly.  Endocr Rev. 2004;25(1):102-152.PubMedGoogle ScholarCrossref
37.
Holdaway  IM, Bolland  MJ, Gamble  GD.  A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.  Eur J Endocrinol. 2008;159(2):89-95.PubMedGoogle ScholarCrossref
38.
Katznelson  L, Laws  ER  Jr, Melmed  S,  et al.  Acromegaly.  J Clin Endocrinol Metab. 2014;99(11):3933-3951.PubMedGoogle ScholarCrossref
39.
Rokkas  T, Pistiolas  D, Sechopoulos  P, Margantinis  G, Koukoulis  G.  Risk of colorectal neoplasm in patients with acromegaly.  World J Gastroenterol. 2008;14(22):3484-3489.PubMedGoogle ScholarCrossref
40.
Dworakowska  D, Gueorguiev  M, Kelly  P,  et al.  Repeated colonoscopic screening of patients with acromegaly.  Eur J Endocrinol. 2010;163(1):21-28.PubMedGoogle ScholarCrossref
41.
Wolinski  K, Czarnywojtek  A, Ruchala  M.  Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly—meta-analysis and systematic review.  PLoS One. 2014;9(2):e88787.PubMedGoogle ScholarCrossref
42.
Abu Dabrh  AM, Mohammed  K, Asi  N,  et al.  Surgical interventions and medical treatments in treatment-naïve patients with acromegaly.  J Clin Endocrinol Metab. 2014;99(11):4003-4014.PubMedGoogle ScholarCrossref
43.
Mercado  M, Gonzalez  B, Vargas  G,  et al.  Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.  J Clin Endocrinol Metab. 2014;99(12):4438-4446.PubMedGoogle ScholarCrossref
44.
Wilson  TJ, McKean  EL, Barkan  AL, Chandler  WF, Sullivan  SE.  Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications.  Pituitary. 2013;16(4):459-464.PubMedGoogle ScholarCrossref
45.
Sandret  L, Maison  P, Chanson  P.  Place of cabergoline in acromegaly: a meta-analysis.  J Clin Endocrinol Metab. 2011;96(5):1327-1335. PubMedGoogle ScholarCrossref
46.
Mercado  M, Borges  F, Bouterfa  H,  et al.  A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.  Clin Endocrinol (Oxf). 2007;66(6):859-868.PubMedGoogle ScholarCrossref
47.
Melmed  S, Cook  D, Schopohl  J, Goth  MI, Lam  KS, Marek  J.  Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy.  Pituitary. 2010;13(1):18-28.PubMedGoogle ScholarCrossref
48.
Colao  A, Bronstein  MD, Freda  P,  et al.  Pasireotide versus octreotide in acromegaly.  J Clin Endocrinol Metab. 2014;99(3):791-799.PubMedGoogle ScholarCrossref
49.
Salvatori  R, Woodmansee  WW, Molitch  M, Gordon  MB, Lomax  KG.  Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States.  Pituitary. 2014;17(1):13-21.PubMedGoogle ScholarCrossref
50.
Muller  AF, Kopchick  JJ, Flyvbjerg  A, van der Lely  AJ.  Clinical review 166.  J Clin Endocrinol Metab. 2004;89(4):1503-1511.PubMedGoogle ScholarCrossref
51.
van der Lely  AJ, Biller  BM, Brue  T,  et al.  Long-term safety of pegvisomant in patients with acromegaly.  J Clin Endocrinol Metab. 2012;97(5):1589-1597.PubMedGoogle ScholarCrossref
52.
Neggers  SJ, de Herder  WW, Feelders  RA, van der Lely  AJ.  Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.  Pituitary. 2011;14(3):253-258.PubMedGoogle ScholarCrossref
53.
Bernabeu  I, Alvarez-Escolá  C, Paniagua  AE,  et al.  Pegvisomant and cabergoline combination therapy in acromegaly.  Pituitary. 2013;16(1):101-108.PubMedGoogle ScholarCrossref
54.
Nieman  LK, Biller  BM, Findling  JW,  et al.  Treatment of Cushing syndrome.  J Clin Endocrinol Metab. 2015;100(8):2807-2831.PubMedGoogle ScholarCrossref
55.
Bertagna  X, Guignat  L.  Approach to the Cushing disease patient with persistent/recurrent hypercortisolism after pituitary surgery.  J Clin Endocrinol Metab. 2013;98(4):1307-1318.PubMedGoogle ScholarCrossref
56.
Molitch  ME.  Current approaches to the pharmacological management of Cushing disease.  Mol Cell Endocrinol. 2015;408(6):185-189.PubMedGoogle ScholarCrossref
57.
Castinetti  F, Guignat  L, Giraud  P,  et al.  Ketoconazole in Cushing disease: is it worth a try?  J Clin Endocrinol Metab. 2014;99(5):1623-1630.PubMedGoogle ScholarCrossref
58.
Vilar  L, Naves  LA, Azevedo  MF,  et al.  Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing disease.  Pituitary. 2010;13(2):123-129.PubMedGoogle ScholarCrossref
59.
Colao  A, Petersenn  S, Newell-Price  J,  et al.  A 12-month phase 3 study of pasireotide in Cushing disease.  N Engl J Med. 2012;366(10):914-924.PubMedGoogle ScholarCrossref
60.
Fleseriu  M, Biller  BMK, Findling  JW, Molitch  ME, Schteingart  DE, Gross  C; SEISMIC Study Investigators.  Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing syndrome.  J Clin Endocrinol Metab. 2012;97(6):2039-2049.PubMedGoogle ScholarCrossref
61.
Fleseriu  M, Molitch  ME, Gross  C, Schteingart  DE, Vaughan  TB  III, Biller  BM.  A new therapeutic approach in the medical treatment of Cushing syndrome.  Endocr Pract. 2013;19(2):313-326.PubMedGoogle ScholarCrossref
62.
Daniel  E, Aylwin  S, Mustafa  O,  et al.  Effectiveness of metyrapone in treating Cushing syndrome.  J Clin Endocrinol Metab. 2015;100(11):4146-4154.PubMedGoogle ScholarCrossref
63.
Baudry  C, Coste  J, Bou Khalil  R,  et al.  Efficiency and tolerance of mitotane in Cushing disease in 76 patients from a single center.  Eur J Endocrinol. 2012;167(4):473-481.PubMedGoogle ScholarCrossref
64.
Preda  VA, Sen  J, Karavitaki  N, Grossman  AB.  Etomidate in the management of hypercortisolaemia in Cushing syndrome: a review.  Eur J Endocrinol. 2012;167(2):137-143.PubMedGoogle Scholar
65.
Beck-Peccoz  P, Lania  A, Beckers  A, Chatterjee  K, Wemeau  JL.  2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors.  Eur Thyroid J. 2013;2(2):76-82.PubMedGoogle ScholarCrossref
66.
Amlashi  FG, Tritos  NA.  Thyrotropin-secreting pituitary adenomas.  Endocrine. 2016;52(3):427-440.PubMedGoogle ScholarCrossref
67.
Pivonello  R, Isidori  AM, De Martino  MC, Newell-Price  J, Biller  BMK, Colao  A.  Complications of Cushing syndrome: state of the art.  Lancet Diabetes Endocrinol. 2016;4(7):611-629.PubMedGoogle ScholarCrossref
68.
Clayton  RN, Jones  PW, Reulen  RC,  et al.  Mortality in patients with Cushing disease more than 10 years after remission.  Lancet Diabetes Endocrinol. 2016;4(7):569-576.PubMedGoogle ScholarCrossref
69.
Nieman  LK, Biller  BM, Findling  JW,  et al.  The diagnosis of Cushing syndrome.  J Clin Endocrinol Metab. 2008;93(5):1526-1540.PubMedGoogle ScholarCrossref
70.
Raff  H.  Cushing syndrome: update on testing.  Endocrinol Metab Clin North Am. 2015;44(1):43-50.PubMedGoogle ScholarCrossref
71.
Petersenn  S, Beckers  A, Ferone  D,  et al.  Therapy of endocrine disease.  Eur J Endocrinol. 2015;172(6):R227-R239.PubMedGoogle ScholarCrossref
72.
Patil  CG, Prevedello  DM, Lad  SP,  et al.  Late recurrences of Cushing disease after initial successful transsphenoidal surgery.  J Clin Endocrinol Metab. 2008;93(2):358-362.PubMedGoogle ScholarCrossref
73.
Ram  Z, Nieman  LK, Cutler  GB  Jr, Chrousos  GP, Doppman  JL, Oldfield  EH.  Early repeat surgery for persistent Cushing disease.  J Neurosurg. 1994;80(1):37-45.PubMedGoogle ScholarCrossref
74.
Starke  RM, Williams  BJ, Vance  ML, Sheehan  JP.  Radiation therapy and stereotactic radiosurgery for the treatment of Cushing disease: an evidence-based review.  Curr Opin Endocrinol Diabetes Obes. 2010;17(4):356-364.PubMedGoogle ScholarCrossref
75.
Lo Re  V  III, Carbonari  DM, Lewis  JD,  et al.  Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status.  Am J Med. 2016;129(3):283-91.e5.PubMedGoogle ScholarCrossref
76.
Freda  PU, Beckers  AM, Katznelson  L,  et al; Endocrine Society.  Pituitary incidentaloma.  J Clin Endocrinol Metab. 2011;96(4):894-904.PubMedGoogle ScholarCrossref
77.
Chanson  P, Raverot  G, Castinetti  F, Cortet-Rudelli  C, Galland  F, Salenave  S; French Endocrinology Society non-functioning pituitary adenoma work-group.  Management of clinically nonfunctioning pituitary adenoma.  Ann Endocrinol (Paris). 2015;76(3):239-247.PubMedGoogle ScholarCrossref
78.
Reincke  M, Allolio  B, Saeger  W, Menzel  J, Winkelmann  W.  The “incidentaloma” of the pituitary gland.  JAMA. 1990;263(20):2772-2776.PubMedGoogle ScholarCrossref
79.
Donovan  LE, Corenblum  B.  The natural history of the pituitary incidentaloma.  Arch Intern Med. 1995;155(2):181-183.PubMedGoogle ScholarCrossref
80.
Nishizawa  S, Ohta  S, Yokoyama  T, Uemura  K.  Therapeutic strategy for incidentally found pituitary tumors (“pituitary incidentalomas”).  Neurosurgery. 1998;43(6):1344-1348.PubMedGoogle Scholar
81.
Feldkamp  J, Santen  R, Harms  E, Aulich  A, Mödder  U, Scherbaum  WA.  Incidentally discovered pituitary lesions.  Clin Endocrinol (Oxf). 1999;51(1):109-113.PubMedGoogle ScholarCrossref
82.
Igarashi  T, Saeki  N, Yamaura  A.  Long-term magnetic resonance imaging follow-up of asymptomatic sellar tumors—their natural history and surgical indications.  Neurol Med Chir (Tokyo). 1999;39(8):592-598.PubMedGoogle ScholarCrossref
83.
Sanno  N, Oyama  K, Tahara  S, Teramoto  A, Kato  Y.  A survey of pituitary incidentaloma in Japan.  Eur J Endocrinol. 2003;149(2):123-127.PubMedGoogle ScholarCrossref
84.
Fainstein Day  P, Guitelman  M, Artese  R,  et al.  Retrospective multicentric study of pituitary incidentalomas [correction appears in Pituitary. 2011 Jun;14(2):198].  Pituitary. 2004;7(3):145-148.PubMedGoogle ScholarCrossref
85.
Arita  K, Tominaga  A, Sugiyama  K,  et al.  Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination.  J Neurosurg. 2006;104(6):884-891.PubMedGoogle ScholarCrossref
86.
Anagnostis  P, Adamidou  F, Polyzos  SA, Efstathiadou  Z, Panagiotou  A, Kita  M.  Pituitary incidentalomas: a single-centre experience.  Int J Clin Pract. 2011;65(2):172-177.PubMedGoogle ScholarCrossref
87.
Dekkers  OM, Hammer  S, de Keizer  RJ,  et al.  The natural course of nonfunctioning pituitary macroadenomas.  Eur J Endocrinol. 2007;156(2):217-224.PubMedGoogle ScholarCrossref
88.
Karavitaki  N, Collison  K, Halliday  J,  et al.  What is the natural history of nonoperated nonfunctioning pituitary adenomas?  Clin Endocrinol (Oxf). 2007;67(6):938-943.PubMedGoogle ScholarCrossref
89.
Honegger  J, Zimmermann  S, Psaras  T,  et al.  Growth modelling of nonfunctioning pituitary adenomas in patients referred for surgery.  Eur J Endocrinol. 2008;158(3):287-294.PubMedGoogle ScholarCrossref
90.
Cheer  K, Trainer  PJ.  Evaluation of pituitary function.  Handb Clin Neurol. 2014;124:141-149.PubMedGoogle Scholar
91.
Kanner  AA, Corn  BW, Greenman  Y.  Radiotherapy of nonfunctioning and gonadotroph adenomas.  Pituitary. 2009;12(1):15-22.PubMedGoogle ScholarCrossref
92.
Colao  A, Di Somma  C, Pivonello  R, Faggiano  A, Lombardi  G, Savastano  S.  Medical therapy for clinically nonfunctioning pituitary adenomas.  Endocr Relat Cancer. 2008;15(4):905-915.PubMedGoogle ScholarCrossref
93.
Vieira Neto  L, Wildemberg  LE, Moraes  AB,  et al.  Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.  Clin Endocrinol (Oxf). 2015;82(5):739-746.PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements